Literature DB >> 32631538

Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors.

Mohamed A Shaaban1, Yaseen A M M Elshaier2, Ali H Hammad3, Nahla A Farag4, Haredy Hassan Haredy5, Ahmed A AbdEl-Ghany6, Khaled O Mohamed7.   

Abstract

A novel series of 1,6-disubstituted pyrazolo[3,4-d]pyrimidin-7-one derivatives, 2a-h, 4a-d, 5 and 6, were successfully synthesized, which showed promising, and potent inhibition of phosphodiesterase 5 (PDE5). The inhibitory activities of 5, 4b, 2a, 2d, 2f, 4d and 4a against PDE5 were similar to that of sildenafil (100%). These compounds exhibited potent relaxant effects on isolated rat cavernosum tissue with pEC50 values ranging from 8.31 to 5.16 µM. Pyrazolo[3,4-d]pyrimidin-7-one scaffolds have been rationally designed via consecutive molecular modelling studies prior to their synthesis and biological evaluation. In addition, the results of the pharmacophore-based virtual screening revealed that 1v0p_PVB might have promising activity as a PDE-5 inhibitor.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cavernosum tissue; Molecular modelling; PDE-5 inhibitors; Phosphodiesterase 5 (PDE5); Pyrazolo[3,4-d]pyrimidin-7-one; Sildenafil

Mesh:

Substances:

Year:  2020        PMID: 32631538     DOI: 10.1016/j.bmcl.2020.127337

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Sulphonated graphene oxide catalyzed continuous flow synthesis of pyrazolo pyrimidinones, sildenafil and other PDE-5 inhibitors.

Authors:  Vinay Kumar Sthalam; Bhushan Mahajan; Purushotham Reddy Karra; Ajay K Singh; Srihari Pabbaraja
Journal:  RSC Adv       Date:  2021-12-21       Impact factor: 3.361

2.  Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.

Authors:  Mater H Mahnashi; Fardous F El-Senduny; Mohammed Abdulrahman Alshahrani; Mahrous A Abou-Salim
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.